Novel therapeutics in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Abstract Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN), i.e., polycythemia vera (PV), essential thrombocythemia (ET), and...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Sangeetha Venugopal, John Mascarenhas
Formato:	Artigo
Idioma:	English
Publicado em:	BMC 2020-12-01
Colecção:	Journal of Hematology & Oncology
Assuntos:	MF ET PV JAK-STAT CALR Ruxolitinib
Acesso em linha:	https://doi.org/10.1186/s13045-020-00995-y

Registos relacionados

Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
Por: Giuseppe Gaetano Loscocco, et al.
Publicado em: (2024-07-01)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
Por: Helna Pettersson, et al.
Publicado em: (2023-08-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Por: Bewersdorf JP, et al.
Publicado em: (2019-12-01)

The Role of New Technologies in Myeloproliferative Neoplasms
Por: Giuseppe A. Palumbo, et al.
Publicado em: (2019-04-01)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
Por: Li Huo, et al.
Publicado em: (2023-01-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
Por: Sophia S. Lee, et al.
Publicado em: (2021-08-01)

Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia Areata
Por: Yotaro Tamai, et al.
Publicado em: (2022-05-01)

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up
Por: Amina Kurtovic-Kozaric, et al.
Publicado em: (2020-05-01)

Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
Por: Ngo Tat Trung, et al.
Publicado em: (2019-06-01)

Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
Por: Velizar Shivarov, et al.
Publicado em: (2024-09-01)

Role of janus kinase inhibitors in the treatment of alopecia areata
Por: Triyangkulsri K, et al.
Publicado em: (2018-07-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
Por: Giuseppe G. Loscocco, et al.
Publicado em: (2021-08-01)

Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function
Por: Iván Parra-Izquierdo, et al.
Publicado em: (2022-04-01)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
Por: Ken-Hong Lim, et al.
Publicado em: (2021-09-01)

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
Por: Sivahari P. Gorantla, et al.
Publicado em: (2024-07-01)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
Por: Camille Keenan, et al.
Publicado em: (2021-02-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
Por: Khaliqur Rahman, et al.
Publicado em: (2024-12-01)

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
Por: Yingxin Sun, et al.
Publicado em: (2021-10-01)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
Por: Ana Micaela Carnaz Simões, et al.
Publicado em: (2022-05-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
Por: Eylem Eliaçık, et al.
Publicado em: (2015-05-01)

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
Por: Tobias Ronny Haage, et al.
Publicado em: (2024-06-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
Por: Mohsen Razavi, et al.
Publicado em: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
Por: Akram Asghari, et al.
Publicado em: (2011-12-01)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
Por: Ana Micaela Carnaz Simões, et al.
Publicado em: (2022-08-01)

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
Por: Fanti Saktini, et al.
Publicado em: (2015-12-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
Por: Fadul A, et al.
Publicado em: (2024-12-01)

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
Por: Keiji Minakawa, et al.
Publicado em: (2021-03-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
Por: T. N. Subbotina, et al.
Publicado em: (2021-06-01)

Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
Por: Arturo Bonometti, et al.
Publicado em: (2023-04-01)

JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review
Por: Faranaz Atschekzei, et al.
Publicado em: (2024-08-01)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
Por: Shin-Yi Chung, et al.
Publicado em: (2021-07-01)

Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit
Por: Xilan Yang, et al.
Publicado em: (2020-03-01)

Remodeling the Bone Marrow Microenvironment – A Proposal for Targeting Pro-inflammatory Contributors in MPN
Por: Jonas Samuel Jutzi, et al.
Publicado em: (2020-08-01)

Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation
Por: Sanjeet ROY, et al.
Publicado em: (2022-01-01)

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
Por: Jona F. Houthuys, et al.
Publicado em: (2022-12-01)

Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
Por: Christopher Puli'uvea, et al.
Publicado em: (2024-12-01)

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
Por: Tobias Idor Boklund, et al.
Publicado em: (2024-05-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
Por: Mostafa Najim, et al.
Publicado em: (2024-12-01)

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition
Por: Hua Zhu, et al.
Publicado em: (2021-07-01)

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
Por: Julian Grabek, et al.
Publicado em: (2020-08-01)